705263-10-1

Basic information

• Product Name: 6-BROMO-PYRAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 6-BROMO-PYRAZOLO[1,5-A]PYRIMIDINE;6-Bromopyrazolo[1,5-a]pyr...;6-broMopyrazolo[1;Pyrazolo[1,5-a]pyriMidine, 6-broMo-
• CAS NO: 705263-10-1
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 705263-10-1.mol
• Article Data: 15

Chemical Properties

• Melting Point: 122-124℃
• Appearance: /
• Density: 1.891g/cm3
• Refractive Index: 1.751
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.81±0.30(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: 6-BROMO-PYRAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-PYRAZOLO[1,5-A]PYRIMIDINE(705263-10-1)
• EPA Substance Registry System: 6-BROMO-PYRAZOLO[1,5-A]PYRIMIDINE(705263-10-1)

Safety Data

• Hazardous Substances Data: 705263-10-1(Hazardous Substances Data)

Usage

Uses

6-Bromopyrazolo[1,5-a]pyrimidine is a reactant in the synthesis of LDN-212854, a selective and potent inhibitor of the BMP type I receptor kinases.

InChI:InChI=1/C6H4BrN3/c7-5-3-8-6-1-2-9-10(6)4-5/h1-4H

Upstream product

• 1820-80-0 3-aminopyrazole 
• 2065-75-0 2-Bromo-malonaldehyde 
• 20591-60-0 (2Z)-2-bromo-3-(dimethylamino)prop-2-enal 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 

Downstream Products

• 1062368-25-5 C₂₁H₂₅N₅O₂ 
• 1109284-33-4 6-bromo-3-iodopyrazolo[1,5-a]pyrimidine 
• 1062368-26-6 tert-butyl 4-(4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenyl)piperazine-1-carboxylate 
• 1062368-49-3 ML₃₄₇ 
• 1062368-61-9 C₁₃H₁₁N₃O 
• 90253-53-5 6-Cyclobutylpyrazolo<1,5-a>pyrimidin 

Relevant articles and documents

SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF

Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.

Synthetic method for 3-bromopyrazolo[1,5-alpha]pyrimidine-6-formic acid

The invention provides a synthetic method for 3-bromopyrazolo[1,5-alpha]pyrimidine-6-formic acid. The synthetic method comprises the following steps: 3-amino-1H-pyrazole is used as a raw material, the3-amino-1H-pyrazole and 2-bromomalonaldehyde are subjected to condensation to obtain 6-bromo-pyrazolo[1,5-alpha]pyrimidine, the 6-bromo-pyrazolo[1,5-alpha]pyrimidine reacts with PdCl2 and triethylamine to obtain methyl pyrazolo[1,5-alpha]pyrimidine-6-formate, a hydrolysis reaction is performed to obtain pyrazolo[1,5-alpha]pyrimidine-6-formic acid, and finally the pyrazolo[1,5-alpha]pyrimidine-6-formic acid reacts with N-bromosuccinimide to obtain the 3-bromopyrazolo[1,5-alpha]pyrimidine-6-formic acid. The synthetic method for the 3-bromopyrazolo[1,5-alpha]pyrimidine-6-formic acid provided bythe invention has a simple synthetic route, a reasonable process and low costs of the raw materials, is simple, easy to obtain and convenient for operation and post treatment, has a high total yield,does not use a highly-toxic reagent, is easy to amplify, and can be used for large-scale production of the 3-bromopyrazolo[1,5-alpha]pyrimidine-6-formic acid.

Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR–ABL kinase inhibitors

A series of 4-((pyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyrazol-1-yl)phenyl-3-benzamide derivatives and 4-((imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-)phenyl-3-benzamide derivatives were designed, synthesized as new BCR–ABL tyrosine kinase inhibitors by using combinational strategies of scaffold hopping and conformational constraint. These new compounds were screened for BCR–ABL1 kinase inhibitory activity, and most of them appeared good inhibitory activity against BCR–ABL1 kinase. One of the most potent compounds 16a strongly suppressed BCR–ABL1 kinase with IC50value of 8.5 nM. The tested compounds 16a and 16i showed strong inhibitory activities against K562 with IC50value of less than 2 nM. Molecular docking studies indicated that these compounds fitted well with the active site of BCR–ABL1 protein. The results showed these inhibitors may serve as lead compounds for further developing new drugs targeted BCR–ABL kinase.